Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a new subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients with ...

NHS England has approved funding for a new sub-cutaneous formulation of Roche’s cancer drug MabThera (rituximab) which offers patients with follicular lymphoma a more convenient treatment option while ...

The European Commission approved a new subcutaneous (SC) formulation of Roche’s MabThera (rituximab) for patients with common forms of non-Hodgkin lymphoma. The approval was the second in six months ...

We note that an intravenous version of MabThera is already marketed by Roche in the EU, the U.S. (known as Rituxan in the U.S.) and other countries for various indications including non-Hodgkin ...

Roche has announced that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera® (rituximab) for people with previously untreated and relapsed/refractory chronic ...

"The start of this Phase 3 subcutaneous MabThera trial in patients with follicular NHL signifies another major achievement for the Halozyme-Roche partnership, and represents the second Roche target to ...

The European Commission has approved a subcutaneous formulation of Roche's MabThera for chronic lymphocytic leukaemia, saving time and easing the treatment burden compared with drug's intravenous form ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission approve Roche's subcutaneous ...

Roche Holding (SIX:ROG) AG (OTC:RHHBY) announced that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients suffering from ...

The FINANCIAL — Roche announced on May 31 that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera® (rituximab) for people with previously untreated and ...

SAN DIEGO, Jan. 24, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has recommended that the European ...